Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor

Neuro-Oncology

Volumn 13, Issue 1, 2011, Pages 99-108

  Crocker, Matthew ^a   Ashley, Sue ^b   Giddings, Ian ^b   Petrik, Vladimir ^a   Hardcastle, Anthea ^b   Aherne, Wynne ^b   Pearson, Andy ^b   Bell, B Anthony ^a   Zacharoulis, Stergios ^b   Papadopoulos, Marios C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Angiogenesis; Glioma; Invasion; Metalloproteinase; Tumor invasion

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ANGIOPOIETIN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 9; INTERCELLULAR ADHESION MOLECULE 3; KERATINOCYTE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STROMELYSIN 2; TIE 1 RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL; CANCER SURVIVAL; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; TUMOR VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INDUCING AGENTS; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICROCIRCULATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 79951664438     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq170     Document Type: Article

References (42)

1. Kirsch M, Schackert G, Black PM. Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol. 2000;50:149-163. (Pubitemid 32166297)
2. Anderson JC, McFarland BC, Gladson CL. New molecular targets in angiogenic vessels of glioblastoma tumors. Expert Rev Mol Med. 2008;10: e23.
3. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol. 2009;92:317-335.
4. Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist. 2009;14:621-636.
5. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;10:740-745.
6. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol. 2009;91:329-336.
7. Schiff D, Purow B. Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme. Nat Clin Pract Oncol. 2008;5:186-187. (Pubitemid 351493675)
8. Martens T, Laabs Y, Günther HS, et al. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res. 2008;14:5447-5458.
9. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63:6962-6970. (Pubitemid 37322983)
10. Puputti M, Tynninen O, Sihto H, et al. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res. 2006;4:927-934. (Pubitemid 46121551)
11. Hassler M, Seidl S, Fazeny-Doerner B, et al. Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genet Cytogenet. 2006;166:46-55.
12. Felsberg J, Rapp M, Loeser S, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009;15:6683-6693.
13. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95. (Pubitemid 46075199)
14. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res. 2008;14:6371-6375.
15. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6:327-338.
16. Whittle IR, Short DM, Deighton RF, Kerr LE, Smith C, McCulloch J. Proteomic analysis of gliomas. Br J Neurosurg. 2007;21:576-582. (Pubitemid 350249199)
17. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
18. http://www.raybiotech.com/manual/antibody%20array/AAH-CYT-G.pdf Accessed Jan 25, 2010.
19. Rasband WS, Image J. U. S. National Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2009.
20. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23:291-299. (Pubitemid 32762920)
21. Aaberg-Jessen C, Christensen K, Offenberg H, et al. Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neurooncol. 2009;95:117-128.
22. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190-198. (Pubitemid 32799739)
23. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99:467-473. (Pubitemid 37040405)
24. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
25. Rafat N, Beck GC, Schulte J, Tuettenberg J, Vajkoczy P. Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg. 2010;112:43-49.
26. Kesari S, Schiff D, Doherty L, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol. 2007;9:354-363. (Pubitemid 47169667)
27. Peles E, Lidar Z, Simon AJ, Grossman R, Nass D, Ram Z. Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery. 2004;55:562-567. (Pubitemid 39186844)
28. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18:708-715. (Pubitemid 30106600)
29. Klement GL, Yip TT, Cassiola F, et al. Platelets actively sequester angiogenesis regulators. Blood. 2009;19:2835-2842.
30. Miller DJ, Wang Y, Kesidis G. Emergent unsupervised clustering paradigms with potential application to bioinformatics. Front Biosci. 2008;13:677-690. (Pubitemid 351606122)
31. Sharma S, Sharma MC, Sarkar C. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology. 2005;46:481-489. (Pubitemid 40632304)
32. Groft LL, Muzik H, Rewcastle NB, et al. Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas. Br J Cancer. 2001;85(1):55-63. (Pubitemid 32695716)
33. Yoshiji H, Harris SR, Raso E, et al. Mammary carcinoma cells overexpressing tissue inhibitor ofmetalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer. 1998;75:81-87. (Pubitemid 28113981)
34. Gouyer V, Conti M, Devos P, et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer 2005;15:1676-1684. (Pubitemid 40490029)
35. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res. 1997;3:1623-1628. (Pubitemid 27431572)
36. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res. 2000;6:4292-299.
37. Lipton A, Ali SM, Leitzel K, et al. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer. 2007;15:1933-1939. (Pubitemid 46744185)
38. Fillmore HL, Van Meter TE, Broaddus WC. Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neurooncol. 2001;53:187-202. (Pubitemid 33034691)
39. Che G, Chen J, Liu L, et al. Transfection of nm23-H1 increased expression of beta-Catenin, E-Cadherin and TIMP-1 and decreased the expression of MMP-2, CD44v6 and VEGF and inhibited the metastatic potential of human non-small cell lung cancer cell line L9981. Neoplasma. 2006;53:530-537. (Pubitemid 46137770)
40. Ylisirniö S, Höyhtyä M, Mä kitaro R, et al. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res. 2001;7:1633-1637. (Pubitemid 32708629)
41. Kargiotis O, Chetty C, Gondi CS, et al. Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene. 2008;14:4830-4840.
42. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009;15:4589-4599.